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INTRODUCTION 
 
There is currently no drug to prevent or slow down the 
progression of AD pathology. Our laboratory uses a 
drug discovery paradigm based upon a set of cell-based 
screening assays that mimic numerous aspects of old 
age-associated neurodegeneration and AD pathology 
[1]. This approach has led to the identification of J147, 
a very potent neuroprotective small molecule that is 
orally active in transgenic human familial AD (hFAD) 
animal models [2, 3].  
 
Age is by far the greatest risk factor for dementia [4]. 
One model of aging is the senescence-accelerated prone 
8 (SAMP8) mouse, that has a progressive, age-
associated decline in brain function similar to human 
AD patients [5, 6]. As they age, SAMP8 mice develop 
an early deterioration in learning and memory as well as 
a number of pathophysiological alterations in  the  brain  
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including increased oxidative stress, inflammation, 
vascular impairment, gliosis, Aβ accumulation and tau 
hyperphosphorylation. Therefore, the SAMP8 mice 
together with their response to J147 may help to 
delineate an understanding of the molecular 
mechanisms that are shared by aging and disease. These 
insights could lead to novel interventions for old age-
associated sporadic AD. 
 
To investigate the interaction between aging and the AD 
drug candidate J147 on brain function as well as brain 
and systemic metabolism, an integrative multi-omics 
approach was carried out in SAMP8 mice. Changes in 
behavior, protein expression, levels of metabolites and 
the whole transcriptome in old SAMP8 mice fed with 
control or J147 diets were compared with young 
SAMP8 control mice. These data identify a subset of 
metabolic changes associated with aging that may be 
relevant to sporadic AD and other forms of dementia. 
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Abstract: Because age is the greatest risk factor for sporadic Alzheimer’s disease (AD), phenotypic screens based upon
old age‐associated brain toxicities were used to develop the potent neurotrophic drug J147. Since certain aspects of aging
may be primary cause of AD, we hypothesized  that  J147 would be effective against AD‐associated pathology  in  rapidly
aging SAMP8 mice and could be used  to  identify  some of  the molecular contributions of aging  to AD. An  inclusive and
integrative multiomics approach was used to investigate protein and gene expression, metabolite levels, and cognition in
old and young SAMP8 mice. J147 reduced cognitive deficits in old SAMP8 mice, while restoring multiple molecular markers
associated with human AD, vascular pathology,  impaired synaptic  function, and  inflammation  to  those approaching  the
young phenotype. The extensive assays used in this study identified a subset of molecular changes associated with aging
that may be necessary for the development of AD.  
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Importantly, the data demonstrate the ability of J147 to 
suppress many of these changes.  
 
RESULTS 
 
To address the effect of J147 on the SAMP8 phenotype, 
two groups of three-month old mice were fed with 
control or J147 diet for an additional seven months, 
while another group of three-month old mice was used 
as a young control group. The SAMP8 mice are an 
inbred strain and, as such, young SAMP8 mice were 
chosen as controls for young age. Given the seven-
month duration of the feeding paradigm, the effect of 
the J147 diet could only be assessed in old SAMP8 
mice, and age-related changes were defined by 
comparison to the young SAMP8 animals. At 10 
months of age, SAMP8 mice present strong age- and 
AD-associated brain deterioration [5-8]. The overall 
goal of this work was to use an in depth multiomics 
approach to identify molecules that mediate the 
physiological effects of J147 on the aging and AD-
associated phenotypes of these mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Behavioral assessment 
 
By monitoring the spontaneous behavior of mice in the 
open field assay, we found a decline in activity 
parameters between the young and the old SAMP8 (Fig. 
1 A-D). J147 had a positive effect on locomotor activity 
as it improved the average velocity and the number of 
vertical counts in the old SAMP8 mice. J147 had no 
effect on the body weights (Fig. S1). 
  
To investigate whether J147 could prevent age-
associated cognitive decline, mice were tested using the 
elevated plus maze (Fig. 1 E), the object recognition test 
(Fig. 1 F) and the Barnes maze (Fig. 1 G). The elevated 
plus maze examines disinhibition behavior based on the 
aversion of normal mice to open spaces. Dementia is 
clinically associated with disinhibition and AD mouse 
models tend to exhibit increased disinhibition [3]. 
Accordingly, old SAMP8 mice spent significantly more 
time in the open arms compared to the young SAMP8 
mice (Fig. 1 E). However, this was not altered by J147 
treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  J147  improves  locomotor  and  cognitive  function  in old  SAMP8 mice. Distance  travelled  (A),
average velocity (B), number of jumps (C) and number of vertical events (D) were assessed in young mice and old
SAMP8 mice fed with control or J147 diets with the open field test. The elevated plus maze (E) was used to measure
anxiety levels. Recognition memory and spatial learning/memory were evaluated by the object recognition (F) and
the Barnes maze  (G) assays, respectively. One‐way ANOVA  followed by Tukey‐Kramer post‐hoc  test and  two‐way
repeated measures ANOVA and post hoc Bonferroni corrected t‐test (n = 12‐16/group). All data are mean ± SD. 
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The object recognition test evaluates recognition 
memory and is based on the spontaneous tendency of 
mice to spend more time exploring a novel object than a 
familiar one. The choice to explore the novel object 
reflects the use of learning and recognition memory. 
There was a significant decrease in the recognition 
index with age in SAMP8 mice, which was reversed by 
J147 (Fig. 1 F). 
 
The Barnes maze is used to analyze spatial learning and 
hippocampal-dependent memory. In this assay, mice 
use visual cues to locate a hidden box. With repeated 
trials, animals with an intact memory show a significant 
reduction in the time (latency) to locate the box. If the 
box is moved to another location in the maze (reversal 
test), normal animals rapidly disengage from the 
previously  learned  information  and  re-learn  the  new  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
location. No changes between the three groups were 
found in the escape latencies during the learning and the 
retention phases (data not shown). However, when 
tested during the reversal phase, which is more sensitive 
to smaller deficits in memory and learning, differences 
were found in the capacity of mice to relearn the new 
location of the escape box (Fig. 1 G). Importantly, J147 
significantly improved learning of the new location. 
Altogether, these data show that J147 prevents the 
deterioration of several aspects of behavior and memory 
that are altered in old SAMP8 mice. 
 
Brain hippocampal protein expression 
 
Western blotting was used to investigate both protein 
alterations underlying the decline in cognitive 
performance of old SAMP8 mice and the therapeutic 
Figure 2. Dysregulation of neuronal homeostasis and  stress  responses  in  the hippocampus of old
SAMP8 mice is partially restored by J147. RIPA‐soluble fractions from hippocampal tissue were analyzed by
Western blotting for relevant markers of neuronal homeostasis and stress and are presented relative to actin or
the  unphosphorylated molecule: Arc  (A),  SAP102  (B),  eIF2α  (C),  peIF2α  (D), HSP40  (E), HSP60  (F), HSP70  (G),
HSP90 (H). One‐way ANOVA followed by Tukey‐Kramer post‐hoc test (n = 6/group). All data are mean ± SD. 
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effects of J147. The expression of activity-regulated 
cytoskeleton-associated protein (Arc) and synapse-
associated protein 102 (SAP102) decreased in old mice 
compared to young mice (Fig. 2 A and B), and treatment 
with J147 prevented these decreases. It was then asked if 
these changes were accompanied by alterations in the 
levels of proteins involved in the cellular responses to 
stress relevant to aging and AD (Fig. 2 C-H). 
Phosphorylation of eukaryotic initiation factor 2a (eIF2α) 
occurs under a variety of stress conditions to control 
protein synthesis. Although total levels of eIF2α were 
decreased in old SAMP8 mice compared to young 
controls, its phosphorylation was increased (Fig. 2 C and 
D), as has been reported in AD patients [9]. Importantly, 
J147 reverted the changes in both the total levels and the 
phosphorylation of eIF2α. Additionally, while the levels 
of heat shock protein 70 (HSP70) were not significantly 
altered between groups, changes in HSP40, HSP60 and 
HSP90 were detected in the old SAMP8 mice (Fig. 2 E-
H). J147 restored HSP60 and HSP90 to levels similar to 
those found in the young control mice.  
 
One hallmark  of  the  AD  brain  is  extracellular  Aβ  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
plaques. Although SAMP8 mice do not develop 
classical plaque pathology, they have a high content of 
Aβ and amyloid deposition around blood vessels [5, 7]. 
Aβ is the product of sequential cleavages of the amyloid 
precursor protein (APP). Processing of APP involves 
the formation of the C83 and C99 C-terminal fragments 
by α and β-secretases, respectively. Amyloidogenic 
processing of C99 by γ-secretase then generates Aβ 
[10]. Although no significant changes in the total levels 
of APP and the C99 and C83 fragments across the three 
groups were identified, there was a trend towards lower 
levels of APP and both the C99 and C83 fragments after 
treatment with J147 (Fig. 3 A and B). More importantly, 
an increase in the level of Aβ1-40 was detected in the 
hippocampus of old SAMP8 mice, which was 
significantly prevented by J147 (Fig. 3 C). Aβ1-42 was 
below the limit of detection (data not shown).  
 
Tau pathology is another important feature of AD. Old 
SAMP8 mice showed increases in both tau protein and 
its phosphorylation at Ser396 (Fig. 3 D and E), an 
epitope affected in the human AD brain [11]. J147 
prevented both of these alterations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. J147 prevents alterations in Aβ and tau homeostasis in the hippocampus of old SAMP8 mice. (A and
B) Western blot analysis of APP processing  in hippocampal  tissue using an antibody against  the C‐terminus of APP. Full‐
length APP and the APP cleavage products C99 and C83 were detected. (C) ELISA for Aβ. Western blot analysis of total Tau
(D) and pTau Ser396 (E). One‐way ANOVA followed by Tukey‐Kramer post‐hoc test (n = 6/group). All data are mean ± SD. 
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Figure 4. Increased inflammation and gliosis in the hippocampus of old SAMP8 mice are prevented by J147.
Western blot analysis of the marker for vascular endothelial inflammation VCAM‐1 (A) and of the IgG (Heavy + Light chains)
content (B). (C) Astrocytosis, measured by Western blot of GFAP  levels. One‐way ANOVA followed by Tukey‐Kramer post‐
hoc test (n = 6/group). (D) Microgliosis was assessed by immunohistochemical (IHC) staining and number of Iba‐1‐positive
cells per mm2 of  total hippocampus calculated. Original magnification: x100. One‐way ANOVA  followed by Tukey‐Kramer
post‐hoc test (n = 8/group). (E and F) Activation of the stress/inflammation‐associated SAPK/JNK was measured by Western
blot  analysis  of  its  phosphorylation  at  Thr183/Tyr185.  One‐way  ANOVA  followed  by  Tukey‐Kramer  post‐hoc  test  (n  =
6/group). All data are mean ± SD.  (G) Quantitative RNA analysis of altered genes  related  to  inflammation. Heatmap and
hierarchical clustering of scaled gene expression with respective fold changes and P values for the comparisons Old/Young
and Old+J147/Old. Scaled expression value (Z‐score)  is plotted  in red–blue color scale with red  indicating high expression
and blue indicating low expression. One‐way ANOVA followed by Tukey‐Kramer post‐hoc test (n = 3‐4/group). 
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Vascular dysfunction and inflammation 
 
Given the relevance of inflammation in aging and AD, a 
detailed characterization of the inflammatory status of 
the aged SAMP8 brain and of the effects of J147 was 
carried out.  AD is often accompanied by 
inflammation of the brain blood barrier (BBB), and the 
disruption of its permeability severely compromises 
neuronal homeostasis [12, 13]. A significant increase in 
the levels of vascular cell adhesion molecule 1 (VCAM-
1), a protein associated with vascular endothelium 
inflammation, was detected in the hippocampus of old 
SAMP8 mice compared to the young SAMP8 controls 
(Fig. 4 A). This increase was completely prevented by 
J147 treatment. In addition, old mice showed 
significantly higher levels of endogenous 
immunoglobulin G (IgG) (Fig. 4 B), a consequence of 
disrupted BBB permeability [14], which was also 
prevented by J147. Together these results suggest that 
J147 helps to preserve BBB homeostasis and vascular 
function in aged SAMP8 mice.  
 
Astrocytes are key constituents of the BBB, and 
astrocytic reactivity is increased in AD [15]. We 
previously reported an increased expression of glial 
fibrillary acidic protein (GFAP), a marker for 
astrocytes, due to an increased number of astrocytes in 
the hippocampus of old SAMP8 mice [7]. The current 
study confirmed an increase in GFAP levels from young 
to old SAMP8 mice and showed that J147 reduced 
GFAP expression (Fig. 4 C). The number of microglia 
increased in the hippocampus of old mice compared to 
young (Fig. 4 D), but J147 did not significantly alter 
their number.  
 
Western blot analysis revealed an activation of the 
stress-activated protein kinase/Jun-amino-terminal 
kinase (SAPK/JNK), determined by its phosphorylation, 
in the hippocampus of old SAMP8 mice (Fig. 4 E and 
F). SAPK/JNK is activated in AD brains and may be the 
cause of abnormal tau phosphorylation [16]. 
Importantly, J147 prevented the activation of 
SAPK/JNK in the old mice.  
 
To expand upon these findings, the expression of a 
comprehensive panel of inflammatory genes was 
analyzed. The expression of a large number of genes was 
altered between young and old SAMP8 mice (50/248); 
most were upregulated (Fig. 4 G). The vast majority of 
changes associated with J147 reverted alterations found 
in old SAMP8 mice toward expression levels in young 
mice. These include mitogen-activated protein kinase 
(MAPK) kinases, such as Map3k7 and Map2k4, that are 
direct activators of SAPK/JNK, in accordance with the 
Western blotting data (Fig. 4 E and F).  
J147 treatment was largely associated with an overall 
decrease in the expression of inflammatory markers in 
old mice, indicative of a reduction in stress-associated 
inflammation. However, the expression of some genes 
that are elevated in old mice, such as the components of 
the complement system C1qa, C1qb, C3 and C4a, were 
not altered by J147.  Interestingly, there was a group of 
inflammation-associated genes whose expression was 
lowered in the old mice. Although most of these were 
not changed by J147, one that was restored by J147 is 
Flt1 that encodes the vascular endothelial growth factor 
receptor 1 and may be related to the effect of J147 on 
the brain vasculature. These data show that J147 
prevents a portion of the pro-inflammatory changes 
associated with aging in the SAMP8 mice. 
 
Eicosanoid metabolism 
 
To further elucidate the effects of J147 on inflammation, 
a detailed analysis of eicosanoid production in the brain 
cortex was conducted. Eicosanoids are a class of 
bioactive lipid mediators derived from the metabolism of 
polyunsaturated fatty acids (PUFAs) by cyclooxygenases 
(COXs), lipoxygenases (LOXs) and cytochrome P450s 
as well as nonenzymatic pathways [17]. They are potent 
regulators of the inflammatory response in the periphery, 
but are much less studied in the brain. Several fatty acids, 
including arachidonic acid (AA), docosahexaenoic acid 
(DHA), linoleic acid (LA) and adrenic acid, as well as 
their respective metabolites were analyzed (Fig. 5). J147 
significantly increased the levels of DHA and restored 
those of adrenic acid. J147 also had a strong anti-oxidant 
effect, since most of the metabolites derived from the 
non-enzymatic oxidation of the different fatty acids were 
decreased in mice treated with J147 as compared to either 
young or old SAMP8 mice. These include the AA-meta-
bolites 9-HETE and 8-iso-15-keto PGF2β; the DHA-
metabolites 11- and 13-HDoHEs; and the LA-metabolites 
9-HODE and 13-HODE. Therefore, J147 may reduce the 
pro-oxidant status in the brain of old animals. 
 
The levels of the cytochrome P450 metabolites 19-
HETE and 20-HETE (AA derivatives), 19(20)-EpDPE 
(DHA derivative) and 9,10-DiHOME (LA derivative), 
which are known regulators of vascular dynamics [18, 
19], were altered with J147 treatment. 20-HETE and 
9,10-DiHOME were also altered by aging and this was 
prevented by J147. In addition, several COX 
metabolites were changed. TXB2, a product of TXA2, 
was increased in old SAMP8 mice and lowered by J147. 
The thromboxane pathway is implicated in platelet 
aggregation, adhesion and vascular contraction during 
inflammation [20]. Thus, these data further support the 
idea that J147 reduces the decline in brain vascular 
health that occurs during aging. 
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Small molecule metabolism 
 
To address the possible therapeutic effects of J147 on 
brain and whole body health, a global metabolic 
profiling study was carried out with blood plasma and 
brain cortical tissue. 195 of 593 (32.9%) and 105 of 493 
(21.3%) assayed biochemicals differed significantly in 
the plasma and cortex, respectively, between the three 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
groups. The heatmaps in Figures 6 A and B depict the 
major altered biological pathways. Global pathway 
changes regarding the metabolism of amino acids, 
peptides and lipids were detected in the plasma (Fig. 6 
A). In the brain, significant changes were associated 
with amino acid and lipid metabolism and, 
importantly, neurotransmission and energy production 
(Fig. 6 B). 
Figure 5. Changes in eicosanoid metabolism of fatty acids in the cortex of young SAMP8, old SAMP8 and old
SAMP8 mice  fed with  J147. Significant changes  in  the metabolites of arachidonic acid, docosahexaenoic acid,  linoleic
acid and adrenic acid derived from the actions of COX and cytochrome P450 and non‐enzymatic oxidation. One‐way ANOVA
followed by Tukey‐Kramer post‐hoc test (n = 5/group). Values are expressed as box‐and‐whisker plots.  
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Figure  6. Metabolomic  analysis  of  plasma
and cortex demonstrate that alterations in
biological  pathways  between  young
SAMP8  and  old  SAMP8 mice  are  partially
rescued  by  J147.  Plasma  (A)  and  cortex  (B)
heatmaps of the biochemicals found significantly
modified, organized by major biological groups.
Scaled  expression  value  (Z‐score)  is  plotted  in
red–blue  color  scale  with  red  indicating  high
expression  and  blue  indicating  low  expression.
Venn  diagrams  illustrating  shared  and  uniquely
affected  metabolites  in  plasma  (C)  and  cortex
(D).  Correlation  of  metabolite  levels  altered  in
Young/Old  and Old+J147/Old  in plasma  (E)  and
cortex  (F)  (units  are  ‐log(fold  change)).  (G)
Selection  of  relevant  biochemicals  changed
between young and old SAMP8 mice affected by
J147,  including  γ‐glutamyl  amino  acids,
dipeptides, BCAAs, acyl  carnitines and PUFAs  in
the  plasma,  and  metabolites  related  to
neurotransmission  and  energetic  pathways  in
the cortex. One‐way ANOVA followed by Tukey‐
Kramer  post‐hoc  test  (n  =  5/group). Values  are
expressed as box‐and‐whisker plots. 
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Venn diagrams highlighting the significant changes in 
plasma and cortex that differentiate the comparisons 
between the young, old and old+J147 groups are shown 
in Figures 6 C and D. Fold changes of the overlapping 
metabolites were correlated between the two 
comparisons (Fig. 6 E and F). Treatment with J147 
rescued changes in all of the 31 plasma metabolites also 
found altered in old SAMP8 mice. This accounts for 
76% of all differences between old SAMP8 treated with 
J147 and old SAMP8 fed with control diet. In the 
cortex, J147 rescued changes in 11 biochemicals (out of 
12), representing 55% of all differences between J147 
treated and untreated old SAMP8 mice.  Figure 6 G 
shows the specific biological groups of metabolites 
found affected in the plasma (for all biochemicals see 
Table S1). Numerous γ-glutamyl amino acids, 
branched-chain amino acids (BCAAs) and dipeptides 
were downregulated with age, while several 
acylcarnitines and PUFAs were highly elevated in the 
old SAMP8 mice. In both cases, J147 reversed most of 
these changes towards the younger phenotype.  
 
To investigate which biological pathways and 
diseases/functions could be associated with these 
alterations, Ingenuity Pathways Analysis (IPA) was 
carried out with biochemicals present in the Human 
Metabolome Database (HMDB). It is important to note 
that many of the metabolites identified in Figure 6 do 
not have an established biological pathway in HMDB; 
therefore, this analysis has limitations. The top 
canonical pathways altered in the plasma are shown in 
Figure S2 A and B, and confirm changes in amino acid, 
protein metabolism, urea cycle and mitochondrial 
energetics (tricarboxycylic acid cycle (TCA) and 
oxidative phosphorylation) found between the young 
and old SAMP8 mice. Some of the diseases and 
functions predicted to be associated with these changes 
relevant to aging include cancer, gastrointestinal and 
hepatic dysfunction, endocrine system, energy 
metabolism and inflammatory responses (Fig. S2 C). 
Most of these were also found associated with the 
metabolites changed by J147, indicative that J147 might 
be rescuing certain aspects of these diseases and 
functions that are changed with age.  
 
Although the total number of metabolites altered in the 
brain of old SAMP8 mice was lower than in the plasma, 
the associations determined by IPA were strong (Fig. S2 
E and F). Some of the metabolites of interest participate 
in energy production processes, amino acid metabolism, 
G protein-coupled receptor (GPCR) and cAMP 
signaling, neuronal homeostasis and lipid metabolism 
(Fig. S2 E) (for all biochemicals see Table S2). 
Specifically, alterations in glycolytic and TCA 
intermediates in old SAMP8 mice (Fig. 6 G) are 
indicative of mitochondrial dysfunction, which is 
characteristic of aging and AD [21]. J147 also preserved 
the levels of glutamate, the principal neurotransmitter in 
the brain and a product of the TCA intermediate α-
ketoglutarate, which was also rescued by J147 (Fig. 6 
G). The levels of cAMP were elevated in old SAMP8 
mice and were lowered by J147. cAMP is an 
intracellular signal transduction molecule crucial for 
many biological processes and its upregulation has been 
associated with AD [22]. The predicted diseases and 
functions are consistent with these alterations and 
include cancer, stress pathways, cellular survival/growth 
and maintenance, neurological disease and energy 
metabolism (Fig. S2 F). 
 
Whole transcriptome 
 
To elucidate how changes in behavior, proteomics and 
metabolomics are related to alterations in gene 
expression, whole transcriptome analysis was carried 
out with hippocampal tissue. 5279 genes were altered 
between the old and young SAMP8 mice and 150 genes 
were changed with J147 treatment (Fig. 7 A). The 
heatmap in Figure 7 B shows a rescuing effect by J147 
of changes verified between the young and old SAMP8 
mice. Correlation of the expression of the overlapping 
121 genes between the two comparisons confirms that 
most of these (116 genes; 77% of total genes changed 
with J147) are indeed associated with a rescue of age-
related changes in gene expression (Fig. 7 C).  
 
The IPA of canonical pathways revealed a number of 
important signaling pathways related to brain function, 
including axonal guidance, G-protein coupled receptor 
(GPCR), protein kinase A (PKA), cAMP and neuronal 
cAMP response element-binding protein (CREB) 
signaling (Fig. 7 D). Importantly, treatment with J147 
altered the expression of genes associated with some of 
these pathways, namely cAMP, GPCR and CREB 
signaling. Also of interest are the changes in the renin-
angiotensin and endothelin-1 signaling in old SAMP8 
mice, which are important regulators of vascular 
function, supporting the Western blotting data regarding 
alterations in the brain vasculature (Fig. 4 A and B). 
 
The large dataset obtained with the whole transcriptome 
allowed for a more informative prediction on the 
diseases and functions associated with aging. These 
included cancer as well as neurological disorders and 
nervous system homeostasis. The mosaics (Fig. 7 E) 
depict the activation state of specific components in 
each disease/function group. It is worth noting that the 
changes associated with J147 are related to decreases in 
neurological disease and increases in neuronal function 
and cancer signaling. The whole transcriptome data 
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also correlated well with the data obtained using the 
Nano-string technology for inflammatory genes (not 
shown). 
 
In summary, the  RNA  analysis  strongly  complements  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the rest of the data presented here and further supports 
the potential protective effects of J147 on the central 
nervous system (CNS) by virtue of its ability to rescue 
specific aspects of aging that are associated with CNS 
dysfunction with particular relevance to AD.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  7. Whole  transcriptome  analysis  of  hippocampus  shows  a  rescue  of  some  age‐related  changes  in  RNA
expression by J147.  (A) Venn diagram  illustrating shared and uniquely affected genes.  (B) Heatmap of  the 150 genes  found
significantly modified between Old, Old+J147 and Young SAMP8 mice. Scaled expression value (Z‐score) is plotted in yellow–blue
color  scale with yellow  indicating high expression and blue  indicating  low expression.  (n = 3‐4/group).  (C) Correlation of gene
expression altered in Young/Old and Old+J147/Old (units are ‐log(fold change)). Predicted canonical biological pathways (D) and
diseases/functions (E) associated with the alterations in gene expression. Only the top significant pathways are indicated.  
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DISCUSSION 
 
We used an integrated multiomics approach to 
investigate the interaction at the molecular level 
between an AD drug candidate and aging in the SAMP8 
model of aging and early sporadic AD. Our data show 
that the detrimental changes in behavior that occur with 
age are accompanied by alterations in protein and RNA 
expression, as well as in the levels of many key 
metabolites. Most importantly, our study identifies a 
large set of parameters in old SAMP8 mice that are 
associated with stress, vascular pathology, and 
inflammation that are also observed in human aging and 
AD. J147 prevented the alteration of many of the 
metabolic parameters of aging as well as features 
directly related to the clinical hallmarks of AD, 
including memory impairment, Aβ content and tau 
hyperphosphorylation.  
 
SAMP8 mice develop a progressive, age-associated 
decline in brain function as well as pathophysiological 
features similar to those found in the brains of sporadic 
AD patients. Therefore, they may represent an excellent 
model for studying the relationship between aging and 
sporadic AD [5, 6]. Our data greatly expand the existing 
knowledge of the age and AD-associated SAMP8 
phenotype at both the brain and system levels. Since the 
positive effects of J147 in old SAMP8 mice included an 
improvement in physical and cognitive parameters, 
reflecting a preservation of their health in general, our 
results suggest that J147 might be acting by preventing 
specific metabolic changes that result as a consequence 
of old age-associated stress. 
 
HSPs represent a major cellular defense against the 
proteotoxic stress that is characteristic of age-related 
neurodegenerative disorders. HSP expression depends 
upon the type of HSP, the disease, cell type and brain 
region [23]. The changes in HSP40, 60 and 90 observed 
in the hippocampus of old SAMP8 mice are indicative 
of stress, and J147 returned the levels of HSP60 and 90 
to those of young mice. eIF2α is also involved in 
protein homeostasis and potentially AD [9]. J147 
returned both its level and phosphorylation state to 
those of young animals. 
 
One of the most prominent manifestations of stress 
during aging is the production of inflammatory 
mediators accompanied by metabolic alterations. 
Although clinical trials with a few anti-inflammatory 
drugs failed to prevent AD disease progression, 
epidemiological studies suggest that long-term use of 
anti-inflammatory drugs may reduce the risk [12]. The 
data presented here show an increase in inflammatory 
parameters in old SAMP8 mice. In the CNS, 
inflammation is often characterized by the activation of 
glial cells, mainly astrocytes and microglia. This age-
associated phenotype is characteristic of the AD brain 
[24]. SAMP8 mice also develop astrogliosis [7], and we 
demonstrate here that J147 reduces astrocytic reactivity.  
Microglia are the resident macrophages of the brain and 
play a central role during inflammation in the aging and 
AD brains [25]. Although J147 did not reduce the 
increased number of microglia cells found in the 
hippocampus of old SAMP8 mice, it reduced activation 
of the stress-induced SAPK/JNK as well as the RNA 
expression of a number of markers of inflammation in 
the brain. Activation of SAPK/JNK is associated with 
the inflammatory response in activated microglia [26] 
and it is possible that J147 preserved microglial 
function without affecting their number. 
 
Interestingly, the altered expression of several 
components of the complement system in old SAMP8 
mice was not changed by J147. This is important given 
that the complement system is also activated in human 
AD patients but that it is thought to be part of a 
neuroprotective response that helps clear apoptotic cells 
and Aβ peptide [27]. Therefore, there are parts of the 
innate immune system that may be beneficial in the 
context of aging and AD. The fact that J147 did not 
alter the levels of these components yet reduced Aβ 
levels, inflammation and vascular pathology supports 
this idea.  
 
A potentially harmful aspect of inflammation in the 
aging brain is that it may lead to the impairment of 
vascular integrity and alterations in neuronal 
homeostasis [13]. Accordingly, aged SAMP8 mice 
display disrupted BBB permeability [14]. Our data 
strongly support the idea that neurovascular 
dysregulation is an important pathophysiological feature 
of brains from old SAMP8 mice, and that J147 may 
protect brain function in these old mice at least in part 
by preserving BBB homeostasis. The evidence includes 
the reduction in the levels of VCAM-1, the prevention 
of IgG infiltration into the hippocampus and the 
modulation of eicosanoids that regulate vascular 
dynamics. 
 
Also important is the observation that J147 significantly 
increased the levels of DHA in the brain. DHA is the 
primary structural fatty acid in the human brain and has 
been linked to cognitive performance. While low 
plasma levels of DHA are associated with cognitive 
decline in elderly and AD patients, higher DHA intake 
and plasma levels inversely correlate with AD risk [28]. 
DHA supplementation in aged animals enhances 
learning and memory, and protects against Aβ and tau 
pathology in AD mouse models [28-30]. The increase in 
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DHA with J147 could be a consequence of its reduced 
oxidation, as suggested by lower levels of its oxidized 
metabolites HDoHes. Furthermore, a dramatic reduction 
of other oxidized eicosanoids was also observed with 
J147 treatment.  
 
Aging is accompanied by strong metabolic alterations at 
the organismal level that are often associated with 
mitochondrial dysfunction [21, 31]. Our analysis of the 
metabolomic profile of the plasma of old SAMP8 mice 
revealed profound changes in several biological pathways 
in comparison to the young SAMP mice. The levels of 
several amino acids and peptides were found lowered in 
the old SAMP8 mice. These included γ-glutamyl amino 
acids, dipeptides and the BCAAs. γ-glutamyl amino acids 
are generated during the γ-glutamyl cycle, which is 
involved in the transport of glutathione (GSH) between 
different organs [32]. GSH is the major intracellular 
antioxidant. Extracellular GSH is usually broken down to 
its constituent amino acids by the enzyme γ-glutamyl 
transpeptidase (GGT) and then those are transported 
across the plasma membrane to regenerate GSH 
intracellularly [32]. This enzymatic reaction transfers the 
γ-glutamyl moiety from GSH to acceptor amino acids. 
The fact that several γ-glutamyl amino acids were lower 
in the plasma of old SAMP8 could be related to impaired 
GSH homeostasis in the mice. 
 
Amino acid metabolism is of particular relevance to 
aging because studies with animals and humans 
strongly suggest that dietary supplementation with 
essential and branched chain amino acids positively 
affects physical health and promotes survival [33]. It 
was proposed that the positive effects of BCAAs are 
directly associated with improvement of mitochondrial 
function [33]. J147 restored to young levels many of the 
alterations in γ-glutamyl amino acids and BCAAs found 
in the old SAMP8 mice, as well as the levels of several 
dipeptides.  
 
In a study that compared the plasma metabolome of 
young with older mice, there was an increase in fatty 
acids (C18:0 and C20:4ω6) with age [34]. Similarly, old 
SAMP8 mice have significantly increased levels of both 
C18:0 and C20:4ω6 (Table S1) as well as many other 
fatty acids, in particular a large group of PUFAs. 
However, in contrast with the earlier report, we found 
striking increases in the levels of several acylcarnitines. 
This is a very important observation because fatty acids 
must be transported into the mitochondria using the 
carnitine shuttle in order to produce energy via β-
oxidation. When mitochondrial β-oxidation is defective, 
plasma levels of acylcarnitines rise, as we found in old 
SAMP8 mice. That J147 restored the levels of 
acylcarnitines suggests a positive effect on 
mitochondrial dynamics. In addition, it has been shown 
that acylcarnitines can directly activate pro-
inflammatory pathways [35], supporting the idea that 
J147 also reduces stress-associated inflammation in old 
age at the systemic level. These data are strengthened 
by the IPA, which identified diseases related to hepatic 
dysfunction and inflammatory responses associated 
with these metabolic alterations. 
 
The analysis of brain metabolites revealed an alteration 
in glycolysis and the TCA cycle in old SAMP8 mice, 
further supporting the idea that mitochondrial function 
is affected with old age. Our data are in accordance with 
a recent study comparing the metabolome of plasma and 
CSF of AD patients and cognitively normal age-
matched controls, where disturbances in multiple 
pathways related to energy metabolism and 
mitochondrial function were identified [36].  
 
J147 had an impact on some of the metabolites within 
the brain, but this was not as pronounced as those found 
in the plasma. However, it did restore the reduced levels 
of glutamate detected in old mice to that of young 
animals. Glutamate can be synthesized from the TCA 
intermediate α-ketoglutarate, which was also restored 
by J147. Glutamate is the major neurotransmitter in the 
brain and is involved in learning and memory processes. 
Studies have shown a decrease in brain glutamate levels 
with aging [37], as well as in the AD brain [38, 39].  
 
Another metabolite altered in the hippocampus of old 
SAMP8 mice whose levels were restored by J147 was 
cAMP. Upregulation of cAMP signaling has been 
implicated in AD physiopathology and increased 
cAMP-PKA signaling in the aging brain is associated 
with impaired cognition and increased vulnerability to 
neurodegeneration [22]. PKA is a tau kinase and its 
dysregulation might be partially responsible for AD-
related abnormal tau phosphorylation [40], which could 
explain in part its increased phosphorylation in the 
hippocampus of old SAMP8 mice and the protection by 
J147. PKA signaling was also one of the canonical 
pathways predicted by the RNA IPA to be affected in 
old mice. 
 
The relevance of cAMP in the old SAMP8 mice and the 
therapeutic effect of J147 were validated by the 
transcriptomic analysis, which identified the cAMP and 
CREB signaling pathways as being significantly altered. 
This is a good example of how omic approaches that 
target different cell physiological components can 
complement each other in order to provide solid 
readouts about relevant pathways. Importantly, changes 
given by J147 were associated with both the cAMP and 
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CREB signaling pathways, suggesting that J147 might 
be exerting its protective effects in the brain by 
preserving the proper function of these pathways. The 
latter result is in agreement with our previous data 
showing that CREB, a transcription factor with a crucial 
role in neuronal plasticity and memory, is activated by 
J147 [3].  
 
Cancer was one of the top diseases associated with 
aging predicted by the IPA from both the RNA and 
metabolite data. Although we have seen no indication of 
tumorigenesis in our SAMP8 model, it is known that the 
incidence of cancer increases with age [41].  The 
changes reported here may thus reflect metabolic 
alterations associated with cellular senescence, a known 
contributor to cancer development [41].  
 
An important observation derived from our multiomics 
approach is that both the metabolomic and transcriptomic 
analyses revealed that the vast majority of the changes 
associated with J147 treatment rescued physiological 
alterations that were observed with aging. These findings 
strongly suggest that J147 might be lowering the AD-
related pathology in old SAMP8 mice by preventing 
some of the deterioration associated with aging.  
 
The purpose of this study was to combine data derived 
from different technological approaches to assess the 
relationship between aging and the therapeutic effects 
of J147 in the SAMP8 mouse model of aging and 
sporadic AD. In this regard, the RNA data showed 
alterations associated with behavior, dysfunction of the 
nervous system and neurological disease. These 
predictions given by the IPA not only are in agreement 
with those found in the metabolite analysis, but also are 
consistent with the cognitive impairment assessed by 
the behavioral testing and the changes in proteins 
required for synaptic function and relevant to AD 
assessed by Western blotting. The IPA also identified 
altered pathways in the old SAMP8 mice linked to 
vascular homeostasis, which are consistent with the 
increased vascular inflammation and BBB disruption 
found with aging, as well as with the changes in 
eicosanoids involved in vascular function.  
 
Overall, the integration of the data acquired with the 
multiple scientific techniques applied here not only 
allowed us to identify with a high level of confidence 
specific pathologies and molecular pathways 
characteristic of old age and critical in AD, but also to 
define a subset that are reverted to youthful levels by 
J147, suggesting that J147 may be effective at treating 
the primary causes of the disease. Finally, our study 
strongly supports the use of this and other rodent 
models of aging that develop AD-related pathology 
[42], to address fundamental questions and test new 
therapeutic interventions. 
 
METHODS 
 
Study design. The aim of this project was to investigate 
whether the AD drug candidate J147 protects SAMP8 
mice from aging and AD-associated pathology and to 
assay the associated metabolic changes. Seventeen 
three-month old male SAMP8 mice were fed with 
control diet (LabDiet 5015, TestDiet, Richmond, IN) 
and eighteen three-month old male SAMP8 mice were 
fed with J147 diet (LabDiet 5015 + 200ppm J147, 
TestDiet) until they reached ten months old. At this age, 
SAMP8 mice present a strong phenotype [7]. The dose 
of J147 used was 200 ppm (∼10mg/kg/day), which 
previously proved effective in AD transgenic mice [2, 
3]. Fourteen three-month old male SAMP8 mice were 
used as the young control group. The SAMP8 mice are 
an inbred strain and, as such, young SAMP8 mice were 
chosen as controls for young age. Given the seven 
month duration of the feeding paradigm, the effect of 
J147 diet could only be assessed in old SAMP8 mice, 
and any age-related changes defined by the comparison 
to the young SAMP8 animals. All mice were randomly 
assigned to experimental groups. The number of mice 
per group was determined based on previous 
experiments [7] and was sufficient to attain statistical 
power. Six old SAMP8 mice fed with control diet and 
two old SAMP8 mice fed with J147 diet died 
throughout the course of this study. Behavioral testing 
was carried out one month prior to sacrifice and 
collection of biological material. Data were analysed by 
blinded researchers when appropriate. 
 
SAMP8 mice. The SAMP8 line was acquired from 
Harlan Laboratories (U.K.). Mouse body weights were 
measured regularly and no significant differences were 
found between the groups (Fig. S1). All experiments 
were performed in accordance with the US Public 
Health Service Guide for Care and Use of Laboratory 
Animals and protocols approved by the IACUC at the 
Salk Institute.  
 
Behavioral assays. For detailed descriptions of the 
materials and methods regarding the open field, the 
elevated plus maze, the object recognition test and the 
Barnes maze assays, please see supplemental 
information. 
 
Tissue preparation. Mice were anesthetized and their 
blood collected by cardiac puncture. After perfusing 
with PBS, their brains were removed. Half of the brain 
was fixed and processed for histology and the other half 
was dissected (to collect cortex and hippocampus) and 
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prepared for Western blot (WB), RNA extraction, 
eicosanoid and metabolomic analysis.  
 
Western blotting. Western blots were carried out as 
described previously [43]. A list of the antibodies used 
can be found in the supplemental information. IgG 
heavy and light chains were detected by blotting the 
membrane directly with the mouse secondary antibody. 
 
Immunohistochemistry. Immunohistochemistry was 
carried out as described previously [43]. Anti-Iba-1 
(#019-19741, 1/4000, from Wako) and biotinylated 
rabbit secondary antibody (#BA1000, 1/400 from 
Vector Laboratories) were used. Number of microglia 
per mm2 of hippocampus was quantified using the 
Image J software (NIH). Total counts in 2-4 sections per 
eight mouse brains of each group were determined in an 
unbiased fashion. 
 
Aβ ELISA. Aβ 1-40 and 1-42 levels in hippocampal 
lysates were analyzed using the Aβ1−40 and Aβ1-42 
ELISA kits from Invitrogen (# KMB3481 and # 
KMB3442, respectively). 
 
Eicosanoid analysis. Eicosanoids were prepared and 
analyzed as described previously [43]. 
 
Metabolomic analysis. Metabolomic analyses were 
conducted at Metabolon as described previously [44]. 
For statistical analyses and data display, any missing 
values were assumed to be below the limits of detection 
and imputed with the compound minimum (minimum 
value imputation).  An estimate of the false discovery 
rate (Q-value) was calculated to take into account the 
multiple comparisons that normally occur in 
metabolomic-based studies, with Q<0.05 used as an 
indication of high confidence in a result. 
 
RNA analysis. RNA was isolated from hippocampus 
using the RNeasy Plus Universal mini kit (Qiagen) and 
RNA analysis performed by Nanostring. 
 
Nanostring: The nCounter GX Mouse Inflammation Kit 
(Nanostring, Seattle, USA) was used to measure a 
comprehensive set of 248 inflammation related mouse 
genes and six internal reference genes.  
 
Whole transcriptome analysis: RNA-Seq libraries were 
prepared using the Illumina TruSeq Stranded mRNA 
Sample Prep Kit according to the manufacturer’s 
instructions. Briefly, poly-A RNA was selected using 
poly dT-beads. mRNA was then fragmented and reverse 
transcribed. cDNA was end-repaired, adenylated and 
ligated with Illumina adapters with indexes. Adapter-
ligated cDNA was then amplified. Libraries were 
pooled and sequenced single-end 50 base-pair (bp) on 
the Illumina HiSeq 2500 platform. Sequencing reads 
were mapped to the mm9 mouse genome using the 
spliced aligner STAR (2.3.0e) with default parameters 
[45]. Indices for the alignment were built using the 
Illumina iGenomes gene annotation for mm9 as a splice 
junction database and the sjdbOverhang parameter set 
to 100. Raw gene-level read counts were calculated 
using this same gene annotation with featureCounts 
(1.4.6) from the Subread package [46]. Expression 
normalization and differential analysis were carried out 
with DESeq2, using a false discovery rate cut-off of 0.1 
[47]. The data discussed in this publication have been 
deposited in NCBI's Gene Expression Omnibus [48] 
and are accessible through GEO Series accession 
number GSE69244 (http://www.ncbi.nlm.nih.gov/geo/ 
query/acc.cgi?acc=GSE69244). 
 
Bioinformatics and statistics. Data in figures is 
presented as group mean ± SD or as box-and-whisker 
plots indicating the group minimum, lower quartile, 
median, upper quartile, and group maximum. Data from 
the Western blotting and eicosanoids analyses were 
normalized to the average of the young SAMP8 control 
group. For metabolites, the measured values across the 
three groups were median-normalized to 1.  
 
Data were analysed and the functional/network analyses 
were generated through the use of QIAGEN’s Ingenuity 
Pathway Analysis (IPA®, QIAGEN Redwood City, 
www.qiagen.com/ingenuity). 
 
Metaboanalyst [49] was used to generate the heatmaps. 
Values were mean-centered and divided by the SD of 
each variable (scaled Z-score). Hierarchical clustering 
of RNA expression was performed using Euclidean 
distances and the Ward algorithm.  
 
Statistical analysis of the three groups was carried out 
by one-way ANOVA followed by Tukey-Kramer 
multiple comparison post hoc test was used. For data 
regarding multiple time points, two-way repeated-
measures ANOVA and post hoc Bonferroni corrected t 
tests were applied. GraphPad Prism 6 was used and 
exact P values are indicated (for P < 0.050). All data are 
mean ± SD. 
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